company background image
ZEAL

Zealand Pharma CPSE:ZEAL Stock Report

Last Price

kr.167.00

Market Cap

kr.7.7b

7D

29.3%

1Y

-8.6%

Updated

04 Oct, 2022

Data

Company Financials +
ZEAL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ZEAL Stock Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

Zealand Pharma A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Pricekr.167.00
52 Week Highkr.213.00
52 Week Lowkr.69.55
Beta1.34
1 Month Change31.19%
3 Month Change66.00%
1 Year Change-8.64%
3 Year Change5.23%
5 Year Change38.02%
Change since IPO110.06%

Recent News & Updates

Shareholder Returns

ZEALDK BiotechsDK Market
7D29.3%7.0%3.5%
1Y-8.6%-7.0%-8.3%

Return vs Industry: ZEAL matched the Danish Biotechs industry which returned -8.9% over the past year.

Return vs Market: ZEAL matched the Danish Market which returned -9.5% over the past year.

Price Volatility

Is ZEAL's price volatile compared to industry and market?
ZEAL volatility
ZEAL Average Weekly Movement11.9%
Biotechs Industry Average Movement8.0%
Market Average Movement5.5%
10% most volatile stocks in DK Market10.5%
10% least volatile stocks in DK Market3.0%

Stable Share Price: ZEAL is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

FoundedEmployeesCEOWebsite
1998237Adam Steensberghttps://www.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
ZEAL fundamental statistics
Market Capkr.7.73b
Earnings (TTM)-kr.1.09b
Revenue (TTM)kr.293.77m

26.3x

P/S Ratio

-7.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZEAL income statement (TTM)
Revenuekr.293.77m
Cost of Revenuekr.112.39m
Gross Profitkr.181.38m
Other Expenseskr.1.27b
Earnings-kr.1.09b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)-23.60
Gross Margin61.74%
Net Profit Margin-371.73%
Debt/Equity Ratio70.9%

How did ZEAL perform over the long term?

See historical performance and comparison